You are here

GSK

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda

Fierce Pharma

Flag link:

GSK plays defense after California judge approves plaintiff's expert testimony in high-stakes Zantac trial

GSK plays defense after California judge approves plaintiff's expert testimony in high-stakes Zantac trial

Fierce Pharma

Flag link:

Chasing Pfizer, GSK's 5-in-1 meningococcal vaccine delivers phase 3 trial win

Chasing Pfizer, GSK's 5-in-1 meningococcal vaccine delivers phase 3 trial win

Fierce Pharma

meningococcal disease

Flag link:

In busy year with Haleon spinoff and Zantac lawsuits, GSK CEO Emma Walmsley scored slight pay raise

In busy year with Haleon spinoff and Zantac lawsuits, GSK CEO Emma Walmsley scored slight pay raise

Fierce Pharma

Flag link:

Pfizer ready to launch RSV vaccines for older adults, pregnant women in US, Europe

Pfizer ready to launch RSV vaccines for older adults, pregnant women in US, Europe

Reuters

Flag link:

Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?

Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?

Yahoo/Zacks.com

Flag link:

FDA advisors recommend GSK’s RSV vaccine for older adults, but flag potential safety risks

FDA advisors recommend GSK’s RSV vaccine for older adults, but flag potential safety risks

CNBC

Flag link:

CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies

CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies

EP Vantage

Gilead Sciences

Flag link:

GSK's bellwether Zantac court date pushed to July

GSK's bellwether Zantac court date pushed to July

Endpoints

Flag link:

GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill

GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill

Yahoo/Reuters

ViiV Healthcare

Gilead Sciences

Flag link:

Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi

Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi

Fierce Pharma

Flag link:

First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness

First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness

Forbes

Moderna Therapeutics

Flag link:

'It's the right call': GSK expresses no regrets on abandoning cell therapy as oligo strategy heats up

'It's the right call': GSK expresses no regrets on abandoning cell therapy as oligo strategy heats up

Fierce Biotech

oligonucleotides

Wave Life Sciences

Flag link:

GSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal trial

GSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal trial

Fierce Biotech

Flag link:

GSK was warned repeatedly about Zantac impurity but played down risks

GSK was warned repeatedly about Zantac impurity but played down risks

Fierce Pharma

Flag link:

GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners

GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners

Fierce Biotech

Vir Biotechnology

Flag link:

Pfizer begins plan to challenge Shingrix with an mRNA vaccine

Pfizer begins plan to challenge Shingrix with an mRNA vaccine

BioPharma Dive

Flag link:

GSK's unusual Jemperli expansion plan wins FDA panel backing—with a twist

GSK's unusual Jemperli expansion plan wins FDA panel backing—with a twist

Fierce Pharma

Flag link:

Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey finds

Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey finds

Fierce Pharma

Flag link:

Pages